Bencina Goran, Billeskov Rolf, Bak Rasmine, Al-Sabbagh Ahmed, Pedersen Julie Højgaard, Lunetcas Marina, Heeno Emma, Tolouee Sara, Ashraf Tuba, Fristrup Niels, Azawi Nessn
MSD Madrid Spain.
MSD Copenhagen Denmark.
BJUI Compass. 2024 Jun 10;5(8):791-798. doi: 10.1002/bco2.375. eCollection 2024 Aug.
This study aimed to characterize the demographic and clinical features of patients with renal cell carcinoma (RCC) post-surgery for localized or locally advanced disease in a national Danish cohort, with a specific focus on describing recurrence patterns in a subgroup aligned with the adjuvant KEYNOTE-564 trial classification.
This was a retrospective analysis of the Danish Renal Cancer (DaRenCa) database. Eligible subjects were individuals with an RCC diagnosis between January 2014 and December 2017 who subsequently underwent radical or partial nephrectomy. Variables of interest were demographic and clinical characteristics, rates and sites of recurrence. Recurrence rates were also assessed in a subpopulation stratified using the risk classifications of the KEYNOTE-564 trial.
A total of 2164 RCC patients were identified. Most patients (84.8%) had non-metastatic RCC (stage M0). A recurrence was observed in 250 of the M0 patients (13.6%). Patients with a recurrence were older, male, had a higher tumour stage, had undergone radical nephrectomy and had a higher Leibovich score. The majority (74.8%) of M0 patients had recurrence at distant metastatic sites. A total of 392 patients were stratified by the KEYNOTE-564 risk classification: 335 intermediate-high risk, 17 high risk and 40 M1 NED (metastatic with no evidence of disease). Recurrence was observed in 37.0%, 88.2% and 27.5% of these risk groups, respectively.
This study elucidates the rates and determinants of post-surgical RCC recurrence in Denmark, underscoring the potential of adjuvant immunotherapy in refining therapeutic strategies, identifying suitable beneficiaries and minimizing overtreatment risks in RCC care.
本研究旨在描述丹麦全国队列中接受局部或局部晚期疾病手术后的肾细胞癌(RCC)患者的人口统计学和临床特征,特别关注描述与辅助性KEYNOTE-564试验分类一致的亚组中的复发模式。
这是一项对丹麦肾癌(DaRenCa)数据库的回顾性分析。符合条件的受试者为2014年1月至2017年12月期间被诊断为RCC且随后接受根治性或部分肾切除术的个体。感兴趣的变量包括人口统计学和临床特征、复发率和复发部位。还使用KEYNOTE-564试验的风险分类对亚组中的复发率进行了评估。
共识别出2164例RCC患者。大多数患者(84.8%)患有非转移性RCC(M0期)。在250例M0期患者中观察到复发(13.6%)。复发患者年龄较大、为男性、肿瘤分期较高、接受过根治性肾切除术且Leibovich评分较高。大多数(74.8%)M0期患者在远处转移部位复发。共有392例患者根据KEYNOTE-564风险分类进行分层:335例中高危、17例高危和40例M1 NED(无疾病证据的转移性)。这些风险组的复发率分别为37.0%、88.2%和27.5%。
本研究阐明了丹麦RCC术后复发的发生率和决定因素,强调了辅助免疫治疗在优化治疗策略、识别合适的受益人群以及将RCC治疗中的过度治疗风险降至最低方面的潜力。